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Abstract
OBJECTIVE—To determine whether rural residents were at a disadvantage compared with urban 
residents with regard to the receipt of curative therapy for prostate cancer.
MATERIALS AND METHODS—Using the Breast and Prostate Cancer Data Quality and 
Patterns of Care Study II, patients with prostate cancer who were diagnosed in 2004 were 
identified. Registrars reviewed the medical records of randomly selected patients with incident 
prostate cancer (n = 1906). The patients’ residential address was geocoded and linked to the 
census tract from the 2000 U.S. Census. The place of residence was defined as rural or nonrural 
according to the census tract and rural-urban commuting area categorization. The distance from 
the residence to the nearest radiation oncology facility was calculated. The odds ratio and 95% 
confidence intervals associated with receipt of noncurative treatment was calculated from logistic 
regression models and adjusted for several potential confounders.
RESULTS—Of the incident patients, 39.1% lived in urban census tracts, 41.5% lived in mixed 
tracts, and 19.4% lived in rural tracts. Hormone-only or active surveillance was received by 15.4% 
of the patients. Relative to the urban patients, the odds ratio for noncurative treatment was 1.01 
(95% confidence interval 0.59–1.74) for those living in mixed tracts and 0.96 (95% confidence 
interval 0.52–1.77) for those living in rural tracts. No association was found for noncurative 
treatment according to the Rural-Urban Commuting Area categorization. The linear trend was null 
between noncurative treatment and the distance to nearest radiation oncology facility (P .92).
CONCLUSION—The choice of curative treatment did not significantly depend on the patient’s 
place of residence, suggesting a lack of geographic disparity for the primary treatment of prostate 
cancer.
Prostate cancer is the most common cancer among men in the United States. During 2011, 
an estimated 240,890 new cases of prostate cancer were diagnosed and 33,720 deaths 
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occurred from the disease.1 Most patients present with localized disease and therefore are 
curable.2 Because of insufficient evidence, no consensus has been reached on the optimal 
treatment of localized prostate cancer, and curative treatment—radical prostatectomy, 
external beam radiotherapy and brachytherapy therapy—are considered to have equivalent 
therapeutic outcomes.3 The choice between these options depends on a number of factors, 
including pretreatment risk classification; the patient’s health status, knowledge, and 
preferences; the physician’s preferences and skills; and the patient’s socioeconomic status.
4–6
 Available evidence suggests that noncurative treatments—in particular, active 
surveillance—might be important treatment considerations for some men diagnosed with 
localized disease,7,8 depending on patient age, comorbidities, cancer stage, and other tumor 
characteristics.9
In the absence of strong scientific evidence to support decision making, studies have 
revealed large variations in the treatment of localized prostate cancer.10 However, limited 
evidence is available on the effect of geography—where a patient lives—on treatment, 
particularly in North America. One hypothesis is that men living in rural areas have greater 
difficulty accessing care, such as radiation facilities, than their nonrural counterparts11 and, 
thus, are less likely to receive curative therapy and more likely to receive noncurative 
treatment. The evidence that exists is inconsistent. A Virginia study found that neither the 
distance to the radiation facility nor the residence (rural or urban) affected receipt of surgery 
vs radiation for prostate cancer but that living in an urban area decreased the likelihood of 
receiving any curative treatment.12 The same study found that the receipt of hormonal 
therapy (compared with surgery or radiation) was less common in men living farther away 
from the radiation facilities. A recent Georgia study showed that rural patients with prostate 
cancer were more likely to receive external beam radiotherapy than surgery.13 A study in the 
Lake Superior region (including parts of Minnesota, Wisconsin, and Michigan) showed that 
rural patients with prostate cancer were at a disadvantage in terms of undergoing disease 
staging, initial management procedures, and participation in cancer clinical trials, but the 
study did not compare treatment.14
Understanding the variation in the treatment of prostate cancer by patient residence is vital, 
especially in the context of evidence that prostate cancer mortality is greater in rural areas of 
the United States.15 Using a statewide, population-based sample of patients with prostate 
cancer, we explored the relationship between geography and primary treatment of 
locoregional prostate cancer in Wisconsin men. Wisconsin as a state has a relatively large 
rural population in which nearly one third of the population lives in rural areas.16
MATERIAL AND METHODS
Patients
As a part of the Breast and Prostate Cancer Data Quality and Patterns of Care Study II (a 
collaboration of the Centers for Disease Control and Prevention, the National Program of 
Cancer Registries, and cancer registries from 7 U.S. states).17 Patients with prostate cancer 
diagnosed in 2004 with pathologically confirmed disease were identified through the 
Wisconsin Cancer Reporting System, a state statutory-mandated cancer registry. Patients 
previously diagnosed with cancer or treated at Veterans Affairs hospitals and cases reported 
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on autopsy or by death certificate only were ineligible for the present study. Of 3220 eligible 
subjects, 1169 patients were randomly selected and their medical records abstracted. Cases 
of invasive prostate cancer were randomly selected across strata defined by race/ethnicity 
and state-specific factors such as patient volume of the facility. Minorities were oversampled 
to increase the statistical power to compare factors by race and ethnicity. The institutional 
review board at the University of Wisconsin-Madison approved the present study.
Data Collection
Certified, trained cancer registrars reviewed and abstracted the inpatient and outpatient 
records from >60 medical facilities across Wisconsin in 2008 and 2009. Patient 
comorbidities (using the Adult Comorbidity Evaluation-27,18 an index with a wide range of 
coexisting conditions relevant to cancer therapy choice and outcome), demographic data, 
diagnostics, tumor characteristics, primary treatment type, and follow-up data for 1 year 
starting from diagnosis were abstracted using the study protocol. Registrars entered the data 
into Abstract Plus (a comprehensive, standardized software program provided by the Centers 
for Disease Control and Prevention) while on-site at the medical facility.
Statistical Analysis
Patients with prostate cancer with a diagnosis of metastatic disease (n = 49) or with an 
unknown disease stage (n = 12)were excluded from the present analysis. An additional 12 
patients with unknown treatment plans were also excluded. Thus, of the 1169 patients with 
abstracted data, 1096 were included in the final analysis. Curative treatment was defined as 
prostatectomy, external beam radiotherapy, brachytherapy, or cryotherapy as the first course 
of treatment of prostate cancer. Noncurative treatment was defined as receiving hormonal 
therapy only or active surveillance or watchful waiting. For the purposes of the present 
analysis, active surveillance and watchful waiting were considered equivalent and both 
categorized as active surveillance.
Several geographic variables were constructed according to the patient’s residence at 
diagnosis. First, the residential addresses were geocoded and linked to the census tracts 
(2000 U.S. Census), and each address was assigned a value for the percentage of census tract 
classified as urban. Second, a code for the rural-urban commuting area (RUCA) was 
assigned to each patient by census tract. RUCA is a classification scheme developed by the 
Office of Rural Health Policy that characterizes each census tract according to the proportion 
of urbanized population from the U.S. Census and information on commuting flow.19 Each 
patient’s residence was further categorized as either urban focused, large rural/town focused, 
small rural town focused, or isolated small rural town focused, using the RUCA 4-tiered 
taxonomy.20 Third, the radiation oncology facility locations in and bordering Wisconsin 
were geocoded. The distance from the patient’s residence to the nearest radiation oncology 
facility was calculated using the North American Association of Central Cancer Registries’ 
great circle distance calculator.21
A secondary analysis assessed the association of receiving radiotherapy vs surgery for 
patients with prostate cancer according to the urban-rural residential classification. Using 
multivariate logistic regression models, we calculated the odds ratios and 95% confidence 
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intervals to assess the association of noncurative treatment with the geographic variables. 
The percentage of census tracts classified as urban and the distance from the residence to the 
nearest radiation oncology facility were analyzed categorically and continuously in separate 
models. The RUCA classification was assessed categorically. The models were adjusted for 
covariates chosen a priori: age at diagnosis (20–54, 55–59, 60–64, 65–69, 70–74, and 75 
years), race/ethnicity (Hispanic, non-Hispanic white, non-Hispanic black, non-Hispanic 
Asian or Pacific Islander, non-Hispanic Native American, or Alaskan Native), Adult 
Comorbidity Evaluation-27 overall comorbidity score (none, mild, moderate, severe, 
unknown), Gleason score (<5, 6, 7, 8, test not done, unknown), insurance category (no 
insurance, private insurance, Medicaid, Medicare, or other public insurance, unknown), 
disease stage (localized, regional), and prediagnosis prostate-specific antigen level (<10 vs 
10 ng/mL). We accounted for the sampling design using sampling weights in logistic 
regression models and in the calculation of percentages. P trends represent ordinal terms in 
regression models. All analyses were performed using SAS, version 9.1, software (SAS 
Institute, Cary, NC).
Sensitivity Analysis
A sensitivity analysis was conducted using only patients with prostate cancer with localized 
disease (n = 877). The results did not change substantially from the results of the analysis of 
localized and regional disease; therefore, the sensitivity analysis results were not shown.
RESULTS
Of the 1096 patients with locoregional prostate cancer, 55.3% elected prostatectomy 
(including cryotherapy, representing 2% of total cases), 29.3% radiotherapy (defined as 
either external beam radiotherapy or brachy-therapy), 5.4% hormonal therapy only, and 
10.0% active surveillance. The clinical, socioeconomic, and geographic characteristics of the 
men in each treatment group are listed in Table 1. In general, men undergoing definitive 
therapy were younger, had fewer health problems, and had a later stage of prostate cancer 
than patients receiving noncurative therapy (hormonal therapy alone or active surveillance). 
With regard to definitive therapy, no difference was noted between the receipt of 
radiotherapy vs surgery relative to patients living in urban areas (odds ratio 1.00, 95% 
confidence interval 0.63–1.61 for urban-rural mixed cases; odds ratio 0.98, 95% confidence 
interval 0.53–1.82 for rural cases).
According to the census tract data, 39.1% of the patients with prostate cancer lived in an 
urban setting, 41.5% in a mixed urban-rural environment, and 19.4% in a rural setting. The 
results of the multivariate-adjusted model revealed little difference in the receipt of therapy 
by patient residence. Relative to urban patients, the odds ratio for noncurative treatment was 
1.01 (95% confidence interval 0.59–1.74) for mixed cases and 0.96 (95% confidence interval 
0.52–1.77) for rural cases (Table 2). Using the percentage of those living in an urban area as 
a continuous variables was not significant (P .84).
Using the RUCA classifications, 70.2% of the patients lived in urban-focused areas, 9.9% 
lived in large rural/town-focused areas, 8.8% in small rural town-focused area, and 11.0% in 
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isolated small rural town-focused areas. The odds ratios for noncurative treatment by RUCA 
categories were not significant (Table 2).
The median distance from the patient’s residence to the nearest radiation oncology facility 
was 4.7 miles (mean 10.8, range 0.1–66.1). The distance from the residence to the nearest 
radiation oncology facility was not significantly associated with noncurative treatment, 
either continuously (P = .92) or categorically (Table 2).
COMMENT
Men diagnosed with localized prostate cancer face a difficult dilemma—which definitive 
therapy, if any, to choose. The lack of randomized prospective data comparing treatment 
modalities has limited the ability to use evidence-based medicine as a decision making tool.3 
Thus, considerable variation exists in the primary treatment of prostate cancer. One 
relatively unexplored area of interest that might further explain the variation in primary 
treatment of prostate cancer is the effect of geography within a given region, specifically the 
effect of a rural vs nonrural place of residence.
Previously, research has recognized differences in health outcomes depending on geography. 
Extensive evidence has shown that living far from a population center creates unique health, 
and healthcare, needs.22 Studies have documented that rural patients with cancer have poorer 
outcomes, a lower quality of cancer care, and limited access to cancer support services and 
clinical trials.23,24 In Wisconsin, where the present study was conducted, a recent study 
found that rural patients with cancer in the state had lower health literacy and lower 
satisfaction with their cancer care than residents from nonrural counties.25
Therefore, it is conceivable that rural patients with prostate cancer might have limited access 
to certain medical technologies, such as availability to radiation oncology facilities. We 
hypothesized that compared with urban residents, rural residents would be less likely to 
undergo definitive therapy. This would then have the potential consequence of more rural 
patients receiving noncurative treatment such as primary androgen deprivation therapy or 
active surveillance. For example, because of advanced age or deleterious comorbidities, a 
rural patients with prostate cancer might not be surgical candidates and therefore would 
otherwise be referred for definitive radiotherapy, a therapy requiring daily treatment sessions 
for ≤ 8 weeks. However, we hypothesized that if no radiation facilities were nearby, a patient 
would, by default, receive noncurative treatment. However, our data showed quite the 
opposite—rural patients were just as likely to receive radiotherapy as urban residents, 
presumably because of ubiquitous radiation facilities.
Previous research has revealed a large amount of regional variation in the frequency of 
radical prostatectomy7,10,26 and radiotherapy27 within the United States. In our cohort, 
radical prostatectomy was the most frequent primary treatment (53%) and did not differ 
according to the patient’s place of residence. In contrast, the 1999 Dartmouth Atlas of 
Health Care noted that the lowest prostatectomy rates in Wisconsin were in the major urban 
areas, including Madison and Milwaukee (1.9/1000 and 1.5/1000, respectively).26 An 
additional 28% of patients in the present study underwent primary radiotherapy, significantly 
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less than that (57%) reported by Lai et al27 for Iowa, a neighboring state, using an analysis 
of the Surveillance, Epidemiology, and End Results data.
One potential explanation for the lack of geographic disparities seen in our study might 
relate to the characteristics unique to Wisconsin. Wisconsin is a relatively homogenous state 
in which racial minority populations are relatively small and geographically clustered. These 
similarities might have then created a culture of similar beliefs, attitudes, and biases toward 
medical interventions, leading to little variation. Alternatively, perhaps Wisconsin has 
developed an efficient system of healthcare delivery that serves the needs of its residents, 
regardless of geography. The Wisconsin healthcare systems and hospitals provide access to 
essentially the entire state. Thus, 95% of the population reside within 15 miles of a hospital,
28
 and Wisconsin has one of the lowest uninsured rates in the United States.29 No remote or 
frontier-designated areas are present in the state. These facts support the findings that the 
access and quality of prostate cancer care in rural areas is comparable to that of urban areas. 
Also, when primary care providers identify abnormalities attributable to prostate cancer, the 
standards of care available to these patients are similar in rural and urban areas.
Others have demonstrated a significant variation in the treatment of localized prostate cancer 
among regions within the United States.10 Our study is the first to analyze the effect of a 
patient’s place of residence on treatment variations within a region, with the inclusion of 
noncurative treatment options such as primary androgen deprivation therapy and active 
surveillance. In addition, our study is the first to analyze the effect of geography on any 
medical condition within the state of Wisconsin.
An important caveat to our analysis should be noted—categorizing geographic regions as 
“urban” or “rural” can be described as challenging, elusive, and unstandardized.19 For the 
purposes of the present study, we used 2 different definitions for urban and rural, using the 
census tract and RUCA codes, both well-accepted methods. These definitions are the same 
used by the Offices of Rural Health in determining grant eligibility for rural funding. Others 
have concluded that use of census tract data is appropriate for analyzing disparities in 
prostate cancer outcomes.30 Other potential limitations to the present analysis included the 
lack of generalizability, no information regarding tobacco usage (which might influence 
eligibility for surgery), and no patient-level socioeconomic data. In addition, we did not have 
patient-level information on decision making nor physician level preferences.
Our analysis had several strengths. The Breast and Prostate Cancer Data Quality and 
Patterns of Care Study II data have extensive details regarding comorbidities and health 
history, because these were verified by professional cancer registrars who had access to each 
patient’s medical charts. Therefore, we were able to accurately account and adjust for these 
patient-specific factors to the extent that the charts were complete. In addition, incident cases 
were randomly chosen from the state’s cancer registry, and minorities were oversampled. To 
perform the analysis, we had access to the latitude and longitude of each patient’s residence, 
allowing for accurate geocoding. Finally, we used >1 definition of rural and nonrural, all of 
which consistently showed the same lack of an association between the choice of therapy 
and residential location, increasing confidence in our findings.
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CONCLUSION
Our data did not demonstrate that rural patients with prostate cancer in Wisconsin are less 
likely to receive curative therapy. These results suggest that there is access to available 
treatment modalities within rural Wisconsin communities. The lack of variation with respect 
to geography suggests that the national trends in practice-level variation in the management 
of prostate cancer result from other factors such as physician training, payer mix, 
reimbursement patterns, culture, and patient preferences. Future research should examine 
other regions of the country with rural populations or an analysis of the difference in quality 
of care between different geographic areas, such has been investigated for other cancers.
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